H

Hualan Biological Bacterin Inc
SZSE:301207

Watchlist Manager
Hualan Biological Bacterin Inc
SZSE:301207
Watchlist
Price: 21.74 CNY -1.09% Market Closed
Market Cap: 13.1B CNY

Hualan Biological Bacterin Inc
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Hualan Biological Bacterin Inc
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
H
Hualan Biological Bacterin Inc
SZSE:301207
Cash & Cash Equivalents
ÂĄ623m
CAGR 3-Years
76%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash & Cash Equivalents
ÂĄ12.2B
CAGR 3-Years
-21%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Cash & Cash Equivalents
ÂĄ9.5B
CAGR 3-Years
92%
CAGR 5-Years
132%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Cash & Cash Equivalents
ÂĄ6.9B
CAGR 3-Years
38%
CAGR 5-Years
42%
CAGR 10-Years
N/A
3SBio Inc
HKEX:1530
Cash & Cash Equivalents
ÂĄ1.4B
CAGR 3-Years
-21%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Cash & Cash Equivalents
ÂĄ1.5B
CAGR 3-Years
135%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hualan Biological Bacterin Inc
Glance View

Market Cap
13.1B CNY
Industry
Biotechnology

In the bustling landscape of biotechnology, Hualan Biological Bacterin Inc. emerges as a formidable player. This Chinese company, rooted in the province of Henan, has carved its niche in the development and manufacture of human vaccines. Hualan's journey began with a focused vision on advancing public health through immunization. Today, it stands among the largest producers of human vaccines in China, adeptly navigating the stringent regulatory environments that govern this critical sector. The company's innovative approach in vaccine research is bolstered by state-of-the-art facilities and an unwavering commitment to quality, enabling it to produce safe, effective, and affordable vaccines. Over the years, Hualan has expanded its portfolio to include vaccines for influenza, rabies, and measles, to name a few, each product carefully developed to meet domestic and international health needs. Hualan Biological Bacterin Inc. generates its revenues substantially through the sale of these vaccines. The company's business model leans heavily on its strong distribution network, which ensures that its products effectively reach healthcare providers and institutions across China. Regulatory approvals for new vaccines further pave the way for market expansion and potential export opportunities, contributing to revenue growth. Furthermore, the company strategically invests in research and development, consistently working on new immunological breakthroughs, thus securing its standing and paving the way for future revenue streams. Through this meticulous combination of development, regulatory savvy, and strategic distribution, Hualan not only sustains its financial health but continues to play a vital role in advancing global public health.

Intrinsic Value
27.61 CNY
Undervaluation 21%
Intrinsic Value
Price
H

See Also

What is Hualan Biological Bacterin Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
623m CNY

Based on the financial report for Dec 31, 2024, Hualan Biological Bacterin Inc's Cash & Cash Equivalents amounts to 623m CNY.

What is Hualan Biological Bacterin Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
17%

Over the last year, the Cash & Cash Equivalents growth was -3%. The average annual Cash & Cash Equivalents growth rates for Hualan Biological Bacterin Inc have been 76% over the past three years , 17% over the past five years .

Back to Top